Posted by Michael Wonder on 27 Mar 2023
Iovance Biotherapeutics completes biologics license application submission for lifileucel in advanced melanoma
24 March 2023 - First TIL therapy BLA submission to US FDA.
Iovance Biotherapeutics today announced it has completed its rolling biologics license application submission to the US FDA for lifileucel.
